Gremmel, Thomas http://orcid.org/0000-0001-9554-7292
Niessner, Alexander
Domanovits, Hans
Frossard, Martin
Sengölge, Gürkan
Steinlechner, Barbara
Sycha, Thomas
Wolzt, Michael
Pabinger, Ingrid
Funding for this research was provided by:
Boehringer Ingelheim (unrestricted grant)
Bayer (unrestricted grant)
Medical University of Vienna
Article History
Received: 28 April 2018
Accepted: 30 July 2018
First Online: 20 August 2018
Change Date: 22 February 2019
Change Type: Correction
Change Details: Correction to:Wien Klin Wochenschr 2018ExternalRef removedUnfortunately, the original version of this article contained two mistakes.The text passage “It should be mentioned here that in the case of apixaban, dose adjustment is not based on GFR. A lower dosage of apixaban …
Conflict of interest
: T. Gremmel: Advisory boards/speaker fees: AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi Sankyo, Pfizer, BMS. A. Niessner: Advisory boards/speaker fees: AstraZeneca, Bayer, Pfizer, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Pfizer; Research grant: Boehringer-Ingelheim. H. Domanovits: Advisory boards/speaker fees: Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Pfizer. M. Frossard: Speaker fees: Shire. G. Sengölge: Advisory boards/speaker fees/unrestricted grants: Merit Medical, A. Menarini Pharma GmbH, Novartis, TauroPharm GmbH. B. Steinlechner: Advisory boards/speaker fees: Mitsubishi Tanabe Pharma GmbH, Octapharma. T. Sycha: Advisory boards/speaker fees: Bayer, Pfizer, Daiichi Sankyo. M. Wolzt: Advisory boards/speaker fees: AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi Sankyo. I. Pabinger: Advisory boards/speaker fees: Bayer, Pfizer, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Pfizer.